Solid Biosciences Inc. Operating Income Loss

• Solid Biosciences Inc. showed a decrease of -38.1% in Operating Income Loss from 2024 to 2025.
• This data is from Solid Biosciences Inc.'s annual report (Form 10-K), filed with the SEC on March 19, 2026.
• XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 10 years of available data (2016 to 2025), Solid Biosciences Inc.'s Operating Income Loss has declined by 600.7%.
• Historical annual values: Fiscal year 2025: -$179.21 million | Fiscal year 2024: -$129.73 million | Fiscal year 2023: -$104.25 million | Fiscal year 2022: -$106.45 million | Fiscal year 2021: -$72.25 million | Fiscal year 2020: -$88.41 million | Fiscal year 2019: -$119.32 million | Fiscal year 2018: -$75.69 million | Fiscal year 2017: -$54.86 million | Fiscal year 2016: -$25.58 million.
• Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: June 20, 2026